DK39892D0 - Peptid - Google Patents
PeptidInfo
- Publication number
- DK39892D0 DK39892D0 DK92398A DK39892A DK39892D0 DK 39892 D0 DK39892 D0 DK 39892D0 DK 92398 A DK92398 A DK 92398A DK 39892 A DK39892 A DK 39892A DK 39892 D0 DK39892 D0 DK 39892D0
- Authority
- DK
- Denmark
- Prior art keywords
- glp
- pct
- agonists
- receptor
- sec
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK92398A DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Peptid |
US08/142,439 US5670360A (en) | 1992-03-25 | 1993-03-23 | Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresponding DNA and recombinant expression systems, and screening assays for GLP-1 agonists and enhancers |
ES93906589T ES2070801T1 (es) | 1992-03-25 | 1993-03-23 | Receptor para el peptido-1 similar al glucagon (glp-1). |
AU37512/93A AU3751293A (en) | 1992-03-25 | 1993-03-23 | Receptor for the glucagon-like-peptide-1 (GLP-1) |
AT93906589T ATE184648T1 (de) | 1992-03-25 | 1993-03-23 | Receptor für das glucagon ähnliches peptid-1 (glp-1) |
DE69326405T DE69326405T2 (de) | 1992-03-25 | 1993-03-23 | Receptor für das Glucagon ähnliches Peptid-1 (GLP-1) |
JP51628793A JP3371379B2 (ja) | 1992-03-25 | 1993-03-23 | グルカゴン様ペプチド−1(glp−1)に対するレセプター |
PCT/EP1993/000697 WO1993019175A1 (en) | 1992-03-25 | 1993-03-23 | Receptor for the glucagon-like-peptide-1 (glp-1) |
EP93906589A EP0586657B1 (en) | 1992-03-25 | 1993-03-23 | Receptor for the glucagon-like-peptide-1 (glp-1) |
DE0586657T DE586657T1 (de) | 1992-03-25 | 1993-03-23 | Receptor für das Glucagon ähnliches Peptid-1 (GLP-1). |
GR950300031T GR950300031T1 (en) | 1992-03-25 | 1995-06-30 | Receptor for the glucagon-like-peptide-1 (glp-1). |
US08/869,477 US5846747A (en) | 1992-03-25 | 1997-06-05 | Method for detecting glucagon-like peptide-1 antagonists and agonists |
US08/935,317 US6051689A (en) | 1992-03-25 | 1997-09-22 | Receptor for the glucagon-like-peptide (GLP-1) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK92398A DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Peptid |
Publications (1)
Publication Number | Publication Date |
---|---|
DK39892D0 true DK39892D0 (da) | 1992-03-25 |
Family
ID=8093079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92398A DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Peptid |
Country Status (10)
Country | Link |
---|---|
US (2) | US5670360A (da) |
EP (1) | EP0586657B1 (da) |
JP (1) | JP3371379B2 (da) |
AT (1) | ATE184648T1 (da) |
AU (1) | AU3751293A (da) |
DE (2) | DE69326405T2 (da) |
DK (1) | DK39892D0 (da) |
ES (1) | ES2070801T1 (da) |
GR (1) | GR950300031T1 (da) |
WO (1) | WO1993019175A1 (da) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US5846747A (en) * | 1992-03-25 | 1998-12-08 | Novo Nordisk A/S | Method for detecting glucagon-like peptide-1 antagonists and agonists |
DK39892D0 (da) * | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
KR0154880B1 (ko) * | 1992-06-15 | 1998-10-15 | 피터 알.셰어러 | 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체 |
JP3515112B2 (ja) * | 1992-08-28 | 2004-04-05 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン・レセプタ |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
EP0716694A4 (en) * | 1993-08-09 | 1997-06-04 | Merck & Co Inc | USE OF THE HUMAN HORMONE GLUCAGON AS A PEPTIDE RECEPTOR 1 |
GB9502830D0 (en) * | 1995-02-14 | 1995-04-05 | Ecole Polytech | Regulation of polypeptide production in cells |
US8592553B2 (en) | 1996-12-13 | 2013-11-26 | Nps Pharmaceuticals, Inc. | Cloned glucagon-like peptide-2 receptors |
JP4106094B2 (ja) * | 1996-12-13 | 2008-06-25 | エヌピーエス アレリックス コーポレーション | クローン化グルカゴン様ペプチド2受容体 |
AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
JP2002528721A (ja) * | 1998-10-23 | 2002-09-03 | グラクソ グループ リミテッド | 核内受容体のリガンド用のアッセイ |
EP1263458B1 (en) | 2000-03-08 | 2005-11-16 | Novo Nordisk A/S | Lowering serum cholesterol |
US6448045B1 (en) * | 2000-03-10 | 2002-09-10 | The Regents Of The University Of California | Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1 |
US20020123071A1 (en) * | 2000-12-04 | 2002-09-05 | Knudsen Sanne Moller | Method of identifying compounds capable of acting as agonists or antagonists of G-protein coupled receptors |
US6642003B2 (en) | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
IL160983A0 (en) | 2001-09-24 | 2004-08-31 | Imp College Innovations Ltd | Use of pyy for preparation of a medicament for modification of feeding behavior |
US6911324B2 (en) * | 2001-10-18 | 2005-06-28 | The Regents Of The University Of California | Induction of beta cell differentiation in human cells |
EP1474163A2 (en) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
ATE432289T1 (de) | 2002-07-04 | 2009-06-15 | Zealand Pharma As | Glp-1 und behandlungsmethode für diabetes |
AU2003268621B2 (en) * | 2002-10-02 | 2009-01-15 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
WO2004071393A2 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r) |
WO2005018536A2 (en) * | 2003-05-23 | 2005-03-03 | Human Genome Sciences, Inc. | Agonist antibodies that specifically bind the glucagon like peptide-1 receptor |
CA2545034C (en) | 2003-11-20 | 2013-03-05 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
EP1694356B1 (en) | 2003-12-09 | 2011-02-16 | Novo Nordisk A/S | Regulation of food preference using glp-1 agonists |
JP2008501765A (ja) | 2004-06-11 | 2008-01-24 | ノボ ノルディスク アクティーゼルスカブ | Glp−1アゴニストを用いた薬剤誘発性肥満の中和 |
CN103173402A (zh) | 2005-06-07 | 2013-06-26 | 洛克菲勒大学 | 胰腺β细胞增殖的刺激 |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
WO2009126709A1 (en) * | 2008-04-09 | 2009-10-15 | Transtech Pharma, Inc. | Ligands for the glp-1 receptor and methods for discovery thereof |
RS56632B1 (sr) | 2008-10-17 | 2018-03-30 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
JP5969461B2 (ja) | 2010-04-27 | 2016-08-17 | ジーランド ファーマ アクティーゼルスカブ | Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用 |
HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
DK3326620T3 (da) | 2010-12-16 | 2020-05-25 | Novo Nordisk As | Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
CN103917241A (zh) | 2011-08-29 | 2014-07-09 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
CA2853884A1 (en) | 2011-11-03 | 2013-05-10 | Zealand Pharma A/S | Glp-1 receptor agonist peptide gastrin conjugates |
WO2013083826A2 (en) | 2011-12-09 | 2013-06-13 | Novo Nordisk A/S | Glp-1 agonists |
AU2013234496B2 (en) | 2012-03-22 | 2017-07-27 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
EP2827845B1 (en) | 2012-03-22 | 2018-12-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
CA2877056A1 (en) | 2012-07-01 | 2014-01-09 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
WO2014016300A1 (en) | 2012-07-23 | 2014-01-30 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
JP2016500682A (ja) | 2012-10-17 | 2016-01-14 | ノヴォ ノルディスク アー/エス | 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸 |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
BR112016008115B1 (pt) | 2013-10-17 | 2024-03-12 | Boehringer Ingelheim International Gmbh | Análogos de glucagon acilados |
WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
BR112016009995B1 (pt) | 2013-11-06 | 2023-04-18 | Zealand Pharma A/S | Compostos agonistas triplos glucagon-glp-1-gip |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
BR112016013832A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico |
EP3091964A1 (en) | 2014-01-09 | 2016-11-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
EP3006045B3 (en) | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
JP6898231B6 (ja) | 2014-10-29 | 2021-07-28 | ジーランド ファーマ アクティーゼルスカブ | Gipアゴニスト化合物及び方法 |
JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン/リキシセナチド固定比処方 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
ES2763329T3 (es) | 2015-04-16 | 2020-05-28 | Zealand Pharma As | Análogo de glucagón acilado |
US10905744B2 (en) | 2015-10-07 | 2021-02-02 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
TWI762706B (zh) | 2017-08-24 | 2022-05-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
ES2960687T3 (es) | 2018-02-02 | 2024-03-06 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante |
WO2019193204A1 (en) | 2018-04-06 | 2019-10-10 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
CN111423506B (zh) * | 2019-11-08 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种glp-1化合物 |
TW202140063A (zh) | 2020-02-18 | 2021-11-01 | 丹麥商諾佛 儂迪克股份有限公司 | 醫藥配方 |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
US20230165939A1 (en) | 2020-04-29 | 2023-06-01 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
EP4210680A1 (en) | 2020-09-07 | 2023-07-19 | Cyprumed GmbH | Improved pharmaceutical formulations of glp-1 receptor agonists |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK39892D0 (da) * | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
-
1992
- 1992-03-25 DK DK92398A patent/DK39892D0/da not_active Application Discontinuation
-
1993
- 1993-03-23 WO PCT/EP1993/000697 patent/WO1993019175A1/en active IP Right Grant
- 1993-03-23 JP JP51628793A patent/JP3371379B2/ja not_active Expired - Lifetime
- 1993-03-23 AU AU37512/93A patent/AU3751293A/en not_active Abandoned
- 1993-03-23 ES ES93906589T patent/ES2070801T1/es active Pending
- 1993-03-23 DE DE69326405T patent/DE69326405T2/de not_active Expired - Lifetime
- 1993-03-23 US US08/142,439 patent/US5670360A/en not_active Expired - Lifetime
- 1993-03-23 EP EP93906589A patent/EP0586657B1/en not_active Expired - Lifetime
- 1993-03-23 DE DE0586657T patent/DE586657T1/de active Pending
- 1993-03-23 AT AT93906589T patent/ATE184648T1/de not_active IP Right Cessation
-
1995
- 1995-06-30 GR GR950300031T patent/GR950300031T1/el unknown
-
1997
- 1997-09-22 US US08/935,317 patent/US6051689A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6051689A (en) | 2000-04-18 |
ATE184648T1 (de) | 1999-10-15 |
AU3751293A (en) | 1993-10-21 |
EP0586657A1 (en) | 1994-03-16 |
DE586657T1 (de) | 1996-01-18 |
DE69326405D1 (de) | 1999-10-21 |
US5670360A (en) | 1997-09-23 |
WO1993019175A1 (en) | 1993-09-30 |
JPH06508765A (ja) | 1994-10-06 |
GR950300031T1 (en) | 1995-06-30 |
ES2070801T1 (es) | 1995-06-16 |
DE69326405T2 (de) | 2000-03-23 |
EP0586657B1 (en) | 1999-09-15 |
JP3371379B2 (ja) | 2003-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK39892D0 (da) | Peptid | |
DK1482042T3 (da) | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren | |
ATE193541T1 (de) | Insulinotropes hormon | |
NO964650D0 (no) | LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff | |
IL112112A (en) | Peptides with growth hormone releasing properties and pharmaceutical compositions containing them | |
IL103750A0 (en) | Bacillus promoter | |
DE69327309T2 (de) | Verwendung eines peptids | |
DK0675956T3 (da) | Nyt protein fra urin betegnet komponent B | |
ES2018750T3 (es) | Un metodo de adn recombinante para la produccion de un antagonista de los receptores de interleucina 1 (il-li) | |
ATE177147T1 (de) | Säugetier-rezeptoren für interleukin 10 (il-10) | |
ATE184022T1 (de) | Neuropeptide y antagoniste | |
ATE106943T1 (de) | Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie. | |
ATE389416T1 (de) | Behandlung von knorpelerkrankungen | |
NO951689L (no) | DNA som koder for en human serotoninreseptor (5-HT4B) og anvendelse av denne | |
ATE279515T1 (de) | Pct-65 serotonin rezeptor | |
DK0652964T3 (da) | Promotor af K. lactis transaldolasegenet og anvendelse heraf | |
DK0773999T3 (da) | OR-1, en orphan-receptor tilhørende kernereceptorfamilien | |
DE59206628D1 (en) | Expression signalpeptid-freier staphylokinasen | |
DE69133340D1 (de) | Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen | |
ATE358682T1 (de) | Klonierte rezeptoren des glukagon-ähnlichen peptids-2 | |
FR2693200B1 (fr) | Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations. | |
ES2059801T3 (es) | Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AHS | Application shelved for other reasons than non-payment |